Asunto(s)
Anomalías Múltiples/diagnóstico , Adolescente , Puntaje de Apgar , Córnea/anomalías , Anomalías Craneofaciales/diagnóstico , Oído/anomalías , Resultado Fatal , Femenino , Edad Gestacional , Deformidades de la Mano/diagnóstico , Hernia Diafragmática/diagnóstico , Humanos , Recién Nacido , Masculino , Cuello/anomalías , Nariz/anomalías , Embarazo , Resultado del Embarazo , Síndrome , Ultrasonografía Prenatal/métodosAsunto(s)
Antibacterianos/administración & dosificación , Bacteriemia/diagnóstico , Cateterismo Venoso Central/efectos adversos , Infección Hospitalaria/diagnóstico , Remoción de Dispositivos , Femenino , Humanos , Recién Nacido , Masculino , Medición de Riesgo , Sensibilidad y Especificidad , Venas UmbilicalesAsunto(s)
Benzotiadiazinas , Broncodilatadores/efectos adversos , Enfermedades en Gemelos , Diuréticos , Humanos , Hiponatremia/inducido químicamente , Síndrome de Secreción Inadecuada de ADH/inducido químicamente , Recién Nacido , Respiración Artificial , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/efectos adversos , Teofilina/efectos adversosRESUMEN
OBJECTIVE: To evaluate safety and efficacy of recombinant human erythropoietin (r-HuEPO)in reducing the need for red cell transfusions in anemia of prematurity. METHODS: forty -two preterm infants (gestational age <32 weeks) were randomly assigned to a "treatment" group (r-HuEPO 400 units/kg every alternate day * 10 doses) or "no treatment" (control) group. All infants on enteral feeds received oral iron 3 mg/kg/day, graded up to 6 mg/kg/day. RESULTS: Higher reticulocyte counts in week 2 and 3 and higher hemoglobin levels in week 4 were noted after treatment with r-HuEPO. Despite stumulated erythropoiesis, the frequency of transfusions could not be reduced with r-HuEPO therapy.Overall, Phlebotomy losses, frequency and volume of redcell transfusions were significantly more in neonates with birthweight <1000 grams compared with those with birthweight >1000 grams (p<0.05). Associated side effects of r-HuEPO such as neutropenia,sepsis, hypertension or increased risk of late death did not occur. CONCLUSION:r-HuEPO therapy was safe without any side effects.Inability of r-HuEPO therapy to minimize red cell transfusions for anemia of prematurity may be explained by a relatively strict red-cell transfusion policy and the desired degree of treatment effect.